GE Healthcare Life Sciences will build a KUBio modular biopharma factory in China for JHL Biotech, a provider of biopharma process development and manufacturing services. The site will be fully operational beginning early 2015, and is located in the Biolake Science Park in Wuhan, China. Pre-designed to meet cGMP requirements, KUBio aims to help manufacturers support global customers in bringing treatments to market more quickly.
GE Healthcare will assemble KUBio at the JHL Biotech site in Wuhan with pre-made modules equipped with GE Healthcare’s technologies for the start-to-finish manufacture of biopharmaceuticals. Also, GE’s Shanghai Fast Trak team will validate the equipment and provide training. The JHL Biotech KUBio facility will have a floor space of approximately 2,400m2 and will contain several of 2,000L single-use bioreactors.
Olivier Loeillot, general manager of Enterprise Solutions, GE Healthcare Life Sciences, said, “The decision of JHL Biotech’s highly experienced team to select KUBio as the basis of its commercial cGMP biopharmaceutical manufacturing capabilities in China is a fantastic endorsement of our complete, turnkey approach. We look forward to working with them to bring the facility online to serve the fast-moving biopharmaceutical industry. A diverse range of customers, including governments and pharmaceutical companies, are continuing to recognize the breadth, depth, simplicity and flexibility of what we offer with KUBio.”
Racho Jordanov, co-founder, president and chief executive officer of JHL Biotech, added, “In realizing our vision of making world-class biopharmaceuticals affordable and accessible to all patients, KUBio was the natural choice. Utilizing manufacturing innovations was always a key part of our strategy and GE Healthcare’s KUBio delivers the technologies we want, with the technical support and training we need.”